M. Konrad

Late relapses evolve from slow-responding subclones in t(12;21)-positive acute lymphoblastic leukemia: evidence for the persistence of a preleukemic clone.

O. Haas, R. Repp, H. Gadner, 2003, Blood.

Clonal variation of the immunogenotype in relapsed ETV6/RUNX1‐positive acute lymphoblastic leukemia indicates subclone formation during early stages of leukemia development

M. König, J. Harbott, O. Haas, 2004, Genes, chromosomes & cancer.

Optimization of PCR-based minimal residual disease diagnostics for childhood acute lymphoblastic leukemia in a multi-center setting

M. Schrappe, C. Bartram, G. Basso, 2007, Leukemia.

persistence of a preleukemic clone t(12;21)-positive acute lymphoblastic leukemia: evidence for the Late relapses evolve from slow-responding subclones in

O. Haas, R. Repp, H. Gadner, 2013 .

Phase I evaluation of an anti-breast carcinoma monoclonal antibody 260F9-recombinant ricin A chain immunoconjugate.

L. Weiner, A. Frankel, R. Comis, 1989, Cancer research.

Screening for leukemia- and clone-specific markers at birth in children with T-cell precursor ALL suggests a predominantly postnatal origin.

B. Nadel, O. Haas, O. Bodamer, 2007, Blood.

A phase I study of recombinant interleukin 2 plus recombinant beta-interferon.

S. Litwin, A. Rudolph, K. Padavic-Shaller, 1988, Cancer research.

Renal cell carcinoma: treatment with recombinant interleukin-2 plus beta-interferon.

A. Rudolph, K. Padavic-Shaller, R. Comis, 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

High incidence and unique features of antigen receptor gene rearrangements in TEL–AML1-positive leukemias

M. Schrappe, J. Dongen, G. Basso, 2004, Leukemia.

Hemorrhagic gastritis as a new dose-limiting toxicity of recombinant tumor necrosis factor.

L. Weiner, K. Padavic-Shaller, R. Comis, 1991, Journal of the National Cancer Institute.